title: Can innate and autoimmune reactivity forecast early and advance stages of age-related macular degeneration?
abstract: Age-related macular degeneration (AMD) is a major cause of central vision loss in persons over 55years of age in developed countries. AMD is a complex disease in which genetic, environmental and inflammatory factors influence its onset and progression. Elevation in serum anti-retinal autoantibodies, plasma and local activation of complement proteins of the alternative pathway, and increase in secretion of proinflammatory cytokines have been seen over the course of disease. Genetic studies of AMD patients confirmed that genetic variants affecting the alternative complement pathway have a major influence on AMD risk. Because the heterogeneity of this disease, there is no sufficient strategy to identify the disease onset and progression sole based eye examination, thus identification of reliable serological biomarkers for diagnosis, prognosis and response to treatment by sampling patient's blood is necessary. This review provides an outline of the current knowledge on possible serological (autoantibodies, complement factors, cytokines, chemokines) and related genetic biomarkers relevant to the pathology of AMD, and discusses their application for prediction of disease activity and prognosis in AMD.
authors.affiliation: Ocular Immunology Laboratory, Casey Eye Institute, School of Medicine, Oregon Health and Science University, Portland, OR, USA. Electronic address: adamusg@ohsu.edu.
authors.forename: Grazyna
authors.initials: G
authors.lastname: Adamus
mesh_terms: D015551:Autoimmunity; D018450:Disease Progression; D005260:Female; D006801:Humans; D008268:Macular Degeneration / Q000175:diagnosis* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011379:Prognosis
keywords: Age-related macular degeneration; Aging; Autoantibodies; Autoimmunity; Chemokines; Complement factors; Cytokines; Factor H; IL-17; Retina